Geneprint's value is not the quantity of data it generates — it is the clinical rigor behind every prediction and recommendation. Every layer of the programme is designed to be explainable, clinically governed, and honest about what it does not yet know.
The engine brings genomic, clinical and biological information together to estimate cancer risk and personalise prevention — but it never operates, or reports, without a defined structure and human oversight.
Germline variants, polygenic risk scores, age, sex and ancestry, family history, personal medical history, previous biopsies and screening results, hormonal factors, lifestyle factors, clinical biomarkers, proteomics, metabolomics, and annual follow-up data.
Risk estimation, risk-driver analysis, screening personalisation, prevention prioritisation, action tracking, and annual comparison against a person's own prior results.
Every prediction Geneprint issues states the cancer type, the risk category, absolute and relative risk where validated, the reference population used, the contributing factors, a confidence level, defined limitations, and a connected action. Geneprint never issues an unexplained AI score.
Polygenic risk scores (PRS) are included in a Geneprint report only when they meet a defined evidentiary bar — not because they are available.
Polygenic scores can perform differently across ancestry groups, because the underlying genomic datasets they were built from have historically underrepresented many populations. Geneprint uses ancestry-aware methods, reports performance limitations openly, avoids overstating precision, and combines PRS with clinical and family history rather than interpreting it alone.
Geneprint keeps clinically established findings and advanced AI/multi-omic findings distinct — in the model, in the report, and in how each is allowed to be used.
Pathogenic hereditary variants, guideline-supported risk factors, established clinical risk models, standard laboratory abnormalities, established screening recommendations, clinically actionable family-history findings, and selected validated polygenic risk scores.
Proteomic and metabolomic risk patterns, integrated multi-omic predictions, biological pathway patterns, and emerging combined risk scores. This layer is never presented as a cancer diagnosis, a cancer-free certificate, definitive evidence that cancer is developing, or a reason to perform invasive testing without clinical review.
Before any report is released to a patient, a defined sequence of human checks takes place.
The purpose of testing, the types of results returned, secondary findings, family implications, storage and sharing, biobanking, future reinterpretation, research participation, and withdrawal rights are all explained and agreed before testing begins.
Encryption in transit and at rest, role-based access, separation of identifiable and molecular data where possible, complete audit logs, hospital-specific permissions, defined retention policies, controlled research access, and jurisdiction-specific hosting where required.
Geneprint partners with qualified laboratories for whole-genome sequencing, routine clinical testing, proteomics, metabolomics, and optional cell-free DNA testing.
The sample kit, quality standards, assay performance requirements, data formats, QC thresholds, sample rejection criteria, turnaround time, reanalysis rights, and reported analytes — this consistency is what makes annual biological comparison reliable over time.
Each partner hospital participates in a consented, governed evidence programme that measures the programme's real-world performance.
Stated plainly, because trust depends on it.